Latest Dabigatran Stories
Kristine Kraft, partner at Schlichter, Bogard & Denton, LLP, notes that Xarelto® is surpassing Pradaxa® in the number of reported adverse events, according to the Institute for Safe
Idarucizumab being evaluated to specifically reverse the anticoagulant effect of PRADAXA RIDGEFIELD, Conn., June 26, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
RIDGEFIELD, Conn., June 20, 2014 /PRNewswire/ -- Boehringer Ingelheim announced today the initiation of a new international study of Pradaxa® (dabigatran etexilate mesylate).
Boehringer Ingelheim GmbH, a German pharmaceutical company, recently announced a settlement for approximately 4,000 claims related to injuries and deaths caused by the blood thinner Pradaxa.
German drugmaker Boehringer Ingelheim has offered to settle almost 4,000 Pradaxa lawsuits in the United States.
German pharmaceutical company Boehringer Ingelheim GmbH has agreed to settle nearly 4,000 claims against the drug company for injuries and deaths caused by the blood thinner Pradaxa.
As Flood Law Group continues to investigate Pradaxa lawsuits, the company Boehringer Ingelheim has just paid $650 million to settle thousands of lawsuits against the drug company, according to
The Long Island, New York law firm of Rudolph F. X. Migliore, P. C.
Additional Novel Oral Anticoagulants are Expected to Gain Approval in China for AF and VTE in the Next Three to Four Years, According to Findings from Decision Resources Group BURLINGTON, Mass.,
A recent settlement announcement involving Pradaxa has been announced by the manufacture, Boehringer Ingelheim. Toledo, Ohio (PRWEB) June 05, 2014 Boehringer